Modality
Vaccine
MOA
C5i
Target
JAK1
Pathway
Amyloid
LGSDMDAngelman
Development Pipeline
Preclinical
Jan 2022
→ Jul 2031
PreclinicalCurrent
NCT06012511
1,516 pts·DMD
2022-01→2031-07·Terminated
1,516 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-185.3y awayInterim· DMD
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Termina…
Catalysts
Interim
2031-07-18 · 5.3y away
DMD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06012511 | Preclinical | DMD | Terminated | 1516 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| MLY-3531 | Mineralys | NDA/BLA | JAK1 | |
| Kemanesiran | Sage | Approved | JAK1 | |
| VYG-2970 | Voyager | Phase 3 | JAK1 |